Wk 12 disease activity predicts wk 24/26 remission/low disease activity with #upadacitinib 15mg in MTX-naïve or inadequate responders to MTX and/or TNFi pts. ≥50% improvement in SJC/TJC at Wk 12 was assoc with wk 24/26 remission/low disease activity. Abs#1237 #ACR21 @RheumNow https://t.co/PAaCe5MAcu